Clinical trials: Nutrition, Healthy
Obesity, Overweight
A Study of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doses
This study is a randomized, double-blind, placebo-controlled, dose-escalation phase I clinical trial. This study consists of two parts: the single-dose escalation study (SAD) in healthy subjects and the multiple-dose escalation…
- Trial name
- NCT07280936
- Testing
- SHR-2906 Injection
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Overweight and Obesity
Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects
Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics of HS235 in Overweight and Obese Otherwise Healthy Subjects
- Trial name
- NCT06714825
- Testing
- HS235
- Where
- Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- 35Pharma Inc., a GSK company
Healthy Infants
Growth, Tolerance, and Functional Biomarkers in Healthy Infants Receiving Dietary Supplements
This is a double-blind, randomized, placebo-controlled nutritional study aimed at investigating growth, tolerance, and functional biomarkers in healthy infants receiving dietary supplements from birth to 2.5 months of age
- Trial name
- NCT07630584
- Testing
- Probiotic dietary supplement
- Where
- 2 sites in Philippines
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Healthy Nutrition
A Follow-up Study of Dragon Study (NCT03520764): to Assess the Growth and Immune-related Outcomes
Dragon follow-up aims to evaluate the growth, allergies, and infections of Chinese subjects up to four years of age who completed the intervention period visit (from Day 0-44 to Week 17) of the Dragon study [EBB16SI08406].
- Trial name
- NCT05476289
- Testing
- No intervention
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Danone Nutricia
Obesity
Safety Study to Evaluate BMS-830216 in Healthy Subjects
The purpose of this study is to evaluate the safety profile, tolerability, and pharmacokinetics of single oral doses from 10 mg up to 1200 mg of BMS-830216 (pro-drug of BMS-819881) in healthy subjects
- Trial name
- NCT00878020
- Testing
- BMS-830216
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Blood Sugar; High, Overweight and Obesity
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Burn, Obesity
- Trial name
- NCT06333496
- Testing
- GLP-1 Booster (GB)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alpine Biotech LLC
Obesity &Amp; Overweight
A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects
This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy, overweight, and obese subjects. The primary objective is to evaluate the effect of orally administered VCT220 tablets on the…
- Trial name
- NCT07065058
- Testing
- Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vincentage Pharma Co., Ltd
Glucose Metabolism Disorders, Health Behavior
Relationship Between Individual Effect of Diet on Postprandial Glycemia and Gut Microbiome Profile in Healthy Subjects
When all the food we eat is digested, it will increase blood glucose. Two people can have different glucose blood levels to the same food and one reason can be bacteria live in our gut.
- Conditions
- Glucose Metabolism Disorders, Health Behavior, Diabetes, Metabolic Disease
- Trial name
- NCT06051318
- Testing
- Standardized breakfast A, Standardized breakfast B
- Where
- Brazil
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- BiomeHub Biotechnology Company
Obesity
A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity
The main objective of this trial is to investigate the effect of BI 1820237 alone, BI 456906 alone, combination of BI 1820237 and BI 456906 versus placebo on brain activity.
- Trial name
- NCT06352424
- Testing
- BI 456906, BI 1820237
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Boehringer Ingelheim
Nutrition
Impact of Protein Formulations on the Stimulation of Muscle Protein Synthesis
The overall objective of this study is to determine the effects of ingesting protein that slowly releases amino acids into the blood vs.
- Trial name
- NCT07501403
- Testing
- Control Protein then Extended Release Nutritional Protein, Extended Release Protein then Control Nutritional Protein
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- VitaKey Inc.
Type 2 Diabetes, Overweight and Obesity
A Phase I Study of GZR18 Injection in Healthy Subjects
This trial is conducted in China. The aim of the trial is to evaluate the safety and tolerability of GZR18 injection in healthy subjects following single dose and once-weekly dose for 2 consecutive weeks until reaching the target…
- Trial name
- NCT06548997
- Testing
- GZR18
- Where
- China
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Overweight, Obesity
A Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy Adults
This study is designed to investigate the effect of treatment with Zovaglutide (ZT002 Injection) on the corrected cardiac QT interval relative to a placebo control in healthy participants.
- Trial name
- NCT07697846
- Testing
- ZT002 injection
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Healthy Obesity, Metabolically
Bread Daily Intake Enriched With Mix Fibers in Metabolic Subjects: Intestinal Microbiota and Metabolic Profile Impact
The level of fibre consumption in France is lower than the national and international recommendations (mean 18.8 g/d for men, 16.4 g/d for women (INCA 2007 Study) instead of 30g/d recommended).
- Trial name
- Breath (NCT03875898)
- Testing
- 150 g bread fortified (15 g mix fibre), 150 g unfortified bread
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bridor
Obesity, Overweight
A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or Overweight
The primary objective of this study is to evaluate the effect of a meal and evening dosing on the pharmacokinetics (PK) of KAI 7535 in healthy participants living with obesity or overweight.
- Trial name
- NCT07294898
- Testing
- KAI-7535
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Kailera
College Students of the School of Physical Education
Sports Nutrition Benefits of Weizmannia Coagulans BC99
To evaluate the clinical efficacy of Weizmannia coagulans BC99 in young Chinese patients with exercise-induced muscle damage compared with placebo, and to explore its effects on inflammatory responses and intestinal microbiota.
- Trial name
- NCT07325409
- Testing
- BC99
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Obesity
A First-Time-In-Human Study in Healthy Subjects
This is a first-time-in-human study. The overall purpose of the study is to assess whether the drug is safe and well tolerated after single, increasing doses.
- Trial name
- FTIH (NCT00857883)
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Normal Healthy Adults
A Research Study to Evaluate BLX-0871 in Healthy Adults
This study will test an oral medicine called BLX-0871, which is being developed to improve metabolic health by activating AMP-activated protein kinase (AMPK), a key regulator of energy balance.
- Trial name
- NCT07140081
- Testing
- BLX-0871
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics
Obesity, Overweight
A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy.
- Trial name
- NCT07654972
- Testing
- LY4174794
- Where
- 3 sites in United States, Singapore
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide.
- Trial name
- NCT05671653
- Testing
- PF-07081532, Semaglutide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy, Overweight
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits.
- Conditions
- Healthy, Overweight, Obesity, Type 2 Diabetes
- Trial name
- NCT06945419
- Testing
- LY4086940
- Where
- 5 sites in United States, Singapore
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company